Changes to patented medicine pricing in Canada may impact rare disease treatments

May 11, 2021 on TheZoomerTV

CRU director Dr. Angela Genge was recently on the TheZoomerTV to discuss how the new pricing rules of the Patented Medicine Prices Review Board (PMPRB) intended to lower the cost of medication could negatively affect new drug launches in Canada. The panel included a rare disease advocate, a Parkinson’s patient as well as policy and industry representatives. It’s a crucial topic for Canadians whose quality of life will be impacted by delays in getting novel treatments onto provincial formulary.

For more on ongoing dementia trials at the CRU, visit